featured
Radiotherapy and Short- vs Intermediate-Term Androgen Suppression ± Zoledronic Acid in Locally Advanced Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Short-Term Androgen Suppression and Radiotherapy Versus Intermediate-Term Androgen Suppression and Radiotherapy, With or Without Zoledronic Acid, in Men With Locally Advanced Prostate Cancer (TROG 03.04 RADAR): 10-Year Results From a Randomised, Phase 3, Factorial Trial
Lancet Oncol 2018 Dec 19;[EPub Ahead of Print], JW Denham, D Joseph, DS Lamb, NA Spry, G Duchesne, J Matthews, C Atkinson, KH Tai, D Christie, L Kenny, S Turner, NK Gogna, T Diamond, B Delahunt, C Oldmeadow, J Attia, A SteiglerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.